Brief: Pharming Group H1 Revenues Up 1% To $97.4 Mln

Pharming

03/08/2023 06:23

Aug 3 (Reuters) - Pharming Group NV  PHAR.AS :
    * PHARMING GROUP REPORTS Q2 AND FIRST HALF 2023 FINANCIAL
RESULTS
    * RUCONEST® BUSINESS PERFORMED STRONGLY IN 2Q 2023; CONTINUE
TO
ANTICIPATE LOW SINGLE DIGIT ANNUAL REVENUE GROWTH
    * STRONG START TO U.S. JOENJA® LAUNCH DURING 2Q 2023; 43
PATIENTS
ON PAID THERAPY AND US$3.8 MILLION REVENUE
    * H1 2023 REVENUES INCREASED 1% TO US$97.4 MILLION, COMPARED
TO 1H
2022
    * OVERALL CASH AND CASH EQUIVALENTS, INCLUDING RESTRICTED
CASH, OF
US$194.1 MILLION AT END OF 2Q 2023
    * STRONG PROGRESS IN EFFORTS TO MAKE LENIOLISIB AVAILABLE TO
APDS
PATIENTS IN KEY MARKETS GLOBALLY - CHMP OPINION EXPECTED 4Q 2023

Source text for Eikon:  ID:nPretNvCXa 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))